The global Duchenne Muscular Dystrophy (DMD) Drugs Market experienced substantial growth in 2022, reaching a total value of USD 2.14 billion. This market is poised for remarkable expansion, with a projected valuation of USD 45.66 billion by 2032 and an impressive compound annual growth rate (CAGR) of 40.5% throughout the forecast period. Several factors contribute to this significant revenue surge, primarily driven by the rising prevalence of DMD and heightened investments in Research Development (RD) by pharmaceutical companies aimed at creating effective treatments for this debilitating disorder.
Duchenne Muscular Dystrophy, a rare genetic ailment predominantly afflicting young males, leads to progressive muscle weakness and eventual loss of muscle function. Since no cure currently exists for DMD, the demand for efficacious drugs to manage the condition is substantial. Additionally, the increasing prevalence of DMD, with an estimated incidence of 1 in every 5,000 male births, serves as a critical catalyst for market revenue growth.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/7760
Pharmaceutical companies are making substantial RD investments to pioneer innovative drugs for DMD treatment. These investments have led to the development of various drugs currently in different stages of clinical trials. These include gene therapies, exon-skipping therapies, and stop codon read-through therapies. Moreover, the proliferation of clinical trials and their high success rates augur well for market revenue growth in the foreseeable future.
Key Takeaways
Drug Type Outlook:
The global Duchenne Muscular Dystrophy Drugs Market is categorized by drug type into corticosteroids, exon skipping, and others. Corticosteroids held the dominant market share in 2022, primarily due to their effectiveness in delaying disease progression and enhancing muscle strength. The availability of multiple approved corticosteroids at a lower cost is fueling the demand for these drugs. Nonetheless, their prolonged usage is associated with adverse effects like weight gain, osteoporosis, and delayed puberty, which may hinder market growth.
Exon skipping drugs are poised to register the most rapid revenue CAGR during the forecast period. These drugs are designed to bypass specific mutations in the Dystrophin gene responsible for causing DMD. The escalating prevalence of Duchenne Muscular Dystrophy and the pressing need for effective therapies are propelling the demand for exon skipping drugs. Several clinical trials are underway to assess their efficacy and safety, with regulatory approvals expected in the near future, thus further propelling revenue growth.
The "Others" category encompasses drugs such as gene therapy, cell therapy, and immunomodulators. Gene therapy holds great promise as it involves delivering functional copies of the dystrophin gene to affected muscles, targeting the root cause of the disease. Cell therapy entails the transplantation of stem cells or myoblasts into damaged muscles to replace impaired muscle fibers.
Route of Administration Outlook:
The global Duchenne Muscular Dystrophy Drugs Market is segmented by route of administration into oral, injectable, and others. In 2022, the injectable segment accounted for a substantial market share, mainly due to the availability of several approved injectable drugs for DMD treatment, including deflazacort and eteplirsen. Injectable drugs are preferred over oral alternatives as they offer a more direct and targeted approach to treatment, reducing the risk of systemic side effects. Additionally, the convenience of injectable drugs, requiring fewer doses compared to oral options, is driving demand.
The oral segment is projected to register the swiftest revenue CAGR during the forecast period. Patients and caregivers prefer oral medications due to their ease of administration and convenience. Several oral drugs, such as prednisone and vamorolone, have shown promising results in clinical trials and are poised to secure regulatory approval in the near future, bolstering revenue growth. Moreover, the increasing focus on developing novel oral formulations like tablets and capsules is expected to further propel market growth within this segment.
The "Others" category encompasses drugs administered through alternative routes, including topical and intravenous. Topical drugs are directly applied to the skin and prove valuable for addressing localized muscle symptoms like pain and inflammation. Intravenous drugs are administered directly into the bloodstream, swiftly treating acute symptoms. The growing emphasis on developing innovative drug delivery systems such as patches and infusions is likely to fuel market growth within the "Others" segment.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/7760
Regional Outlook:
North America currently holds the dominant position in the Duchenne Muscular Dystrophy (DMD) drugs market, boasting the highest revenue share in 2021. This can be attributed to the presence of key market players and robust research and development activities within the region. Moreover, the escalating incidence of DMD in North America serves as a significant driving force behind the demand for DMD drugs. According to the Muscular Dystrophy Association, approximately 1 in every 5,000 males in the United States is affected by DMD. Furthermore, the region is witnessing a surge in healthcare spending and government initiatives aimed at supporting the research and development of new DMD drugs.
The European DMD drugs market is poised for substantial growth during the forecast period. The mounting prevalence of DMD in European countries such as the UK, France, and Germany plays a pivotal role in driving market expansion. According to the European Medicines Agency, DMD affects approximately 1 in every 3,500 male births in Europe. Additionally, the region is experiencing an uptick in research and development activities targeting DMD drugs, coupled with increased healthcare expenditure and government initiatives.
The Asia Pacific DMD drugs market is expected to witness significant growth in the forecast period. This can be attributed to the rising prevalence of DMD in emerging countries like India and China. As per the Muscular Dystrophy Foundation India, DMD's prevalence in India is estimated to be around 1 in every 5,000 male births. Furthermore, increased healthcare spending and government support for research and development of new DMD drugs in the region are anticipated to drive market growth.
In summary, North America leads the DMD drugs market with the highest revenue share, while Europe and the Asia Pacific regions are poised for substantial growth, driven by the increasing prevalence of DMD and rising healthcare expenditure.
Competitive Landscape:
Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness. The DMD drugs market is highly competitive, with several major players vying for market share. Some of the key players in the global DMD drugs market include:
- Sarepta Therapeutics, Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Bristol-Myers Squibb Company
- BioMarin Pharmaceutical Inc.
- Santhera Pharmaceuticals
- PTC Therapeutics, Inc.
- Vertex Pharmaceuticals Incorporated
- Abeona Therapeutics
- Catabasis Pharmaceuticals
These companies are at the forefront of DMD drug development and are actively contributing to the growth of the market.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/7760
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Diabetic Foot Ulcers Treatment Market
Deoxyribonucleic Acid (DNA) Testing Market
Doppler Ultrasound System Market
Infection Prevention Devices Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
